First Faculty of Medicine, Charles University, Prague, Czech Republic.
Department of Internal Medicine, Masaryk Hospital, Ústí nad Labem, Czech Republic.
Diabetes Technol Ther. 2022 Dec;24(12):859-867. doi: 10.1089/dia.2022.0152. Epub 2022 Sep 22.
The aim was to compare the efficacy of real-time continuous glucose monitoring (rtCGM) and intermittently scanned continuous glucose monitoring (isCGM) focusing on glycated hemoglobin (HbA1c) as the primary endpoint. The CORRIDA LIFE was a 12-month, real-world, nonrandomized study that is part of the CORRIDA clinical trials program. The study compared rtCGM (Dexcom G5 or G6) and isCGM (FreeStyle Libre 14-Day; Abbott) in adults with type 1 diabetes (T1D). Only patients on multiple daily insulin injections or continuous subcutaneous insulin infusion with no automatic functions were included in this study. Primary outcome was the difference in HbA1c between study groups at 12 months. One hundred ninety-one adults with T1D (mean age 40 ± 13 years, HbA1c 8.1% ± 3.4% [65 ± 14 mmol/mol]) participated in this study; 81 patients initiated rtCGM and 110 initiated isCGM. After 12-months, HbA1c was significantly lower with rtCGM versus isCGM (7.1% ± 3.1% [54.1 ± 10.1 mmol/mol] vs. 7.7% ± 3.3% [61.2 ± 12.2 mmol/mol]), = 0.0001. The percentage of time in hypoglycemia (<70 mg/dL [<3.9 mmol/L]) was lower among rtCGM vs. isCGM participants [4.3% ± 2.8% vs. 6.4% ± 5.3%], = 0.003). Patients with rtCGM spent less time in clinically significant hypoglycemia (<54 mg/dL [<3.0 mmol/L]) (0.9% ± 1.0% vs. 2.3% ± 2.5%, < 0.0001) and more time in target range (70-180 mg/dL [3.9-10 mmol/L]) than isCGM users (67.5% ± 14.8% vs. 57.8% ± 17.0%), = 0.0002. rtCGM was superior to isCGM in HbA1c, hypoglycemia, and other glycemic outcomes. Our findings provide guidance to clinicians when discussing monitoring options with their patients. The study was registered at www.clinicaltrials.gov (NCT04759495).
目的是比较实时连续血糖监测（rtCGM）和间歇性扫描连续血糖监测（isCGM）在糖化血红蛋白（HbA1c）作为主要终点方面的疗效。CORRIDA LIFE 是一项为期 12 个月的真实世界、非随机研究，是 CORRIDA 临床试验项目的一部分。该研究比较了 191 名患有 1 型糖尿病（T1D）的成年人中 rtCGM（Dexcom G5 或 G6）和 isCGM（FreeStyle Libre 14 天；Abbott），他们接受了多次每日胰岛素注射或无自动功能的持续皮下胰岛素输注。主要结局是 12 个月时两组间 HbA1c 的差异。 191 名患有 T1D 的成年人（平均年龄 40±13 岁，HbA1c 8.1%±3.4%[65±14mmol/mol]）参与了这项研究；81 名患者开始使用 rtCGM，110 名患者开始使用 isCGM。12 个月后，rtCGM 组的 HbA1c 明显低于 isCGM 组（7.1%±3.1%[54.1±10.1mmol/mol]vs.7.7%±3.3%[61.2±12.2mmol/mol]），=0.0001。rtCGM 组的低血糖（<70mg/dL [<3.9mmol/L]）时间百分比低于 isCGM 组[4.3%±2.8% vs.6.4%±5.3%]，=0.003]。rtCGM 组的患者发生临床显著低血糖（<54mg/dL [<3.0mmol/L]）的时间更少（0.9%±1.0% vs.2.3%±2.5%，<0.0001），而目标范围内（70-180mg/dL [3.9-10mmol/L]）的时间更多（67.5%±14.8% vs.57.8%±17.0%），=0.0002。rtCGM 在 HbA1c、低血糖和其他血糖结果方面优于 isCGM。我们的研究结果为临床医生在与患者讨论监测选择时提供了指导。该研究在 www.clinicaltrials.gov 上注册（NCT04759495）。
